Microvideos for Improving HPV Vaccination Among Childhood Cancer Survivors

This exploratory mixed-methods study aims to examine receipt of treatment and decision-making among rural cancer patients in Utah. Guided by Conceptual Model of Healthcare Access, the study will integrate, survey and cancer registry data with patient interviews to better understand how travel burden, socioeconomic conditions, health literacy, and other contextual factors shape treatment location and access to care . While the setting of this research is specific to Utah, a state with vast rural regions and only one National Cancer Institute (NCI)-designated cancer center, the findings may inform policy and practice improvements in other states with similar geographic and healthcare infrastructure. Thus, the study has potential relevance for advancing rural cancer equity nationwide.

Understanding how rural cancer patients make treatment decisions is essential to addressing persistent disparities in cancer care access and outcomes. While geographic barriers and structural inequities are well-documented, less is known about the individual and contextual factors that shape patients' choices about where and how to receive treatment. This mixed-methods study will examine receipt of treatment, decision-making, and patient experience among rural cancer patients in Utah, with attention to travel burden, referral pathways, health literacy, and perceived barriers to care.

Study Overview

• Status: Recruiting
• Conditions: HPV Vaccination
• Intervention / Treatment: Behavioral: Microvideos: HPV Vaccination Education

• Study Type: Interventional
• Enrollment (Estimated): 55
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Echo Warner, MPH, PhD, SB; Phone Number: 801-244-7040; Email: echo.warner@hci.utah.edu

Study Locations

• United States
  • Utah
    • Salt Lake City, Utah, United States, 84112
      • Recruiting
      • University of Utah
      • Contact: Echo Warner, MPH, PhD, SB; Phone Number: 801-244-7040; Email: echo.warner@hci.utah.edu
      • Principal Investigator: Echo Warner, MPH, PhD, SB

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Eligible participants include cancer survivors who are currently ages 18-26 years and who were diagnosed with childhood cancer (ages 0-26 at diagnosis) in the past ten years.
• Currently use Facebook or willing to create a Facebook account to use for the duration of the study.
• At the time of enrollment, have not completed all recommended doses of the HPV vaccine.

Exclusion Criteria:

• Unable to speak and understand English.
• Participants who take part in the Aim 1 focus groups will be ineligible for the Aim 2 social media group.
• Participants who are fully vaccinated for HPV will be ineligible as the goal of Aim 2 is to evaluate the feasibility of the social media campaign for improving vaccine intention among HPV unvaccinated individuals.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: HPV Vaccination Education; Microvideos are designed to be <2 minutes long and to address key information on a topic in an engaging and concise manner. HPV vaccine education will be provided to unvaccinated emerging adult survivors of childhood cancer through a pilot quasi-experimental social media intervention.	Behavioral: Microvideos: HPV Vaccination Education; To educate survivors of childhood cancers about a key cancer prevention strategy, HPV vaccination. The core microvideos will focus on the 5 Ws of HPV vaccination: Who should get vaccinated, What HPV vaccination protects against, When to get vaccinated, Where to access the vaccine, Why it matters-designed particularly for cancer survivors.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Feasibility of Microvideo education	Feasibility will be defined as ≥80% of participants completing the intervention and study surveys.	up to 4 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Acceptability of Microvideo Education	Acceptability will be summarized using means, standard deviations, and proportions of participants indicating strong agreement (scores ≥4 out of 5) with positive statements about the microvideos and platform. Scores range from 0-5, with higher scores indicating more positivity about the microvideos and platform, and lower scores indicating less positivity about the microvideos and platform.	up to 4 weeks
Satisfaction Acceptability of Microvideo Education	Satisfaction will be summarized using means, standard deviations, and proportions of participants indicating strong agreement (scores ≥4 out of 5) with positive statements about the microvideos and platform. Scores range from 0-5, with higher scores indicating more positivity about the microvideos and platform, and lower scores indicating less positivity about the microvideos and platform.	up to 4 weeks
HPV Vaccine Intention	To assess HPV vaccine intention among unvaccinated emerging adult survivors of childhood cancer through a pilot quasi-experimental social media intervention. This outcome measure will report the count of participants who intended to receive the HPV Vaccine after the microvideo education.	up to 4 weeks

Collaborators and Investigators

• Sponsor: University of Utah
• Collaborators: Prevent Cancer Foundation; Huntsman Cancer Institute
• Investigators: Principal Investigator: Echo Warner, MPH, PhD, SB, Huntsman Cancer Institute/ University of Utah

Study record dates

Study Major Dates

• Study Start (Estimated): July 1, 2026
• Primary Completion (Estimated): May 1, 2027
• Study Completion (Estimated): May 1, 2027

Study Registration Dates

• First Submitted: May 27, 2026
• First Submitted That Met QC Criteria: June 9, 2026
• First Posted (Actual): June 15, 2026

Study Record Updates

• Last Update Posted (Actual): June 15, 2026
• Last Update Submitted That Met QC Criteria: June 9, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Other Study ID Numbers: 198894

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No